Provider: Nature Publishing Group
Content: application/x-research-info-systems
TY  - JOUR
AU  - Winer, E. P.
TI  - Phase II multicenter study to evaluate the efficacy and safety of Tarceva (Erlotinib HCl, OSI-774) in women with previously treated, locally advanced or metastatic breast cancer
JA  - Breast Cancer Res. Treatm.
PY  - 2002///
VL  - 76
ER  -

TY  - JOUR
AU  - Blackwell, K.
TI  - A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer
JA  - Proc. Am. Soc. Clin. Oncol.
PY  - 2004///
VL  - 23
ER  -

TY  - JOUR
AU  - Dees, E. C.
TI  - Clinical summary of 67 heavily pre-treated patients with metastatic carcinomas treated with GW572016 in a phase Ib study
JA  - Proc. Am. Soc. Clin. Oncol.
PY  - 2004///
VL  - 23
ER  -

TY  - JOUR
AU  - Campos, S. M.
TI  - A phase 2, single agent study of CI-1033 administered at two doses in ovarian cancer patients who failed platinum therapy
JA  - Proc. Am. Soc. Clin. Oncol.
PY  - 2004///
VL  - 23
ER  -

TY  - JOUR
AU  - Baselga, J.
TI  - Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer
JA  - J. Clin. Oncol.
PY  - 2005///
VL  - 23
SP  - 5323
EP  - 5333
M3  - 10.1200/JCO.2005.08.326
N1  - 10.1200/JCO.2005.08.326
UR  - http://dx.doi.org/10.1200/JCO.2005.08.326
ER  -

TY  - JOUR
AU  - Bacus, S. S.
AU  - Beresford, P. J.
AU  - Yarden, Y.
AU  - Spector, N.
AU  - Smith, B.
TI  - The use of predicting factors and surrogate markers in patients' cancer biopsies treated with targeted antibodies to erbB receptors and erbB tyrosine kinase inhibitors
JA  - Proc. Am. Soc. Clin. Oncol.
PY  - 2003///
VL  - 22
ER  -

TY  - JOUR
AU  - Burris, H. A.
TI  - EGF10004: a randomized, multicenter, phase Ib study of the safety, biologic activity and clinical efficacy of the dual kinase inhibitor GW572016
JA  - Breast Cancer Res. Treatm.
PY  - 2003///
VL  - 82
ER  -

TY  - JOUR
AU  - Spector, N. L.
TI  - Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies
JA  - J. Clin. Oncol.
PY  - 2005///
VL  - 23
SP  - 2502
EP  - 2512
M3  - 10.1200/JCO.2005.12.157
N1  - 10.1200/JCO.2005.12.157
UR  - http://dx.doi.org/10.1200/JCO.2005.12.157
ER  -

TY  - JOUR
AU  - Soltoff, S. P.
AU  - Carraway, K. L.
AU  - Prigent, S. A.
AU  - Gullick, W. G.
AU  - Cantley, L. C.
TI  - ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor
JA  - Mol. Cell. Biol.
PY  - 1994///
VL  - 14
SP  - 3550
EP  - 3558
ER  -

TY  - JOUR
AU  - Kim, H. H.
AU  - Sierke, S. L.
AU  - Koland, J. G.
TI  - Epidermal growth factor-dependent association of phosphatidylinositol 3-kinase with the erbB3 gene product
JA  - J. Biol. Chem.
PY  - 1994///
VL  - 269
SP  - 24747
EP  - 24755
ER  -

TY  - JOUR
AU  - Kantarjian, H.
TI  - Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia
JA  - N. Engl. J. Med.
PY  - 2002///
VL  - 346
SP  - 645
EP  - 652
M3  - 10.1056/NEJMoa011573
N1  - 10.1056/NEJMoa011573
UR  - http://dx.doi.org/10.1056/NEJMoa011573
ER  -

TY  - JOUR
AU  - Muller, W. J.
AU  - Sinn, E.
AU  - Pattengale, P. K.
AU  - Wallace, R.
AU  - Leder, P.
TI  - Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene
JA  - Cell
PY  - 1988///
VL  - 54
SP  - 105
EP  - 115
M3  - 10.1016/0092-8674(88)90184-5
N1  - 10.1016/0092-8674(88)90184-5
UR  - http://dx.doi.org/10.1016/0092-8674(88)90184-5
ER  -

TY  - JOUR
AU  - Slamon, D. J.
TI  - Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
JA  - Science
PY  - 1987///
VL  - 235
SP  - 177
EP  - 182
M3  - 10.1126/science.3798106
N1  - 10.1126/science.3798106
UR  - http://dx.doi.org/10.1126/science.3798106
ER  -

TY  - JOUR
AU  - Moody, S. E.
TI  - Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis
JA  - Cancer Cell
PY  - 2002///
VL  - 2
SP  - 451
EP  - 461
M3  - 10.1016/S1535-6108(02)00212-X
N1  - 10.1016/S1535-6108(02)00212-X
UR  - http://dx.doi.org/10.1016/S1535-6108(02)00212-X
ER  -

TY  - JOUR
AU  - Moasser, M. M.
AU  - Basso, A.
AU  - Averbuch, S. D.
AU  - Rosen, N.
TI  - The tyrosine kinase inhibitor ZD1839 ([ldquo]Iressa[rdquo]) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells
JA  - Cancer Res.
PY  - 2001///
VL  - 61
SP  - 7184
EP  - 7188
ER  -

TY  - JOUR
AU  - Moulder, S. L.
TI  - Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo
JA  - Cancer Res.
PY  - 2001///
VL  - 61
SP  - 8887
EP  - 8895
ER  -

TY  - JOUR
AU  - Anderson, N. G.
AU  - Ahmad, T.
AU  - Chan, K.
AU  - Dobson, R.
AU  - Bundred, N. J.
TI  - ZD 1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression
JA  - Int. J. Cancer
PY  - 2001///
VL  - 94
SP  - 774
EP  - 782
M3  - 10.1002/ijc.1557
N1  - 10.1002/ijc.1557
UR  - http://dx.doi.org/10.1002/ijc.1557
ER  -

TY  - JOUR
AU  - Campiglio, M.
TI  - Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level
JA  - J. Cell. Physiol.
PY  - 2004///
VL  - 198
SP  - 259
EP  - 268
M3  - 10.1002/jcp.10411
N1  - 10.1002/jcp.10411
UR  - http://dx.doi.org/10.1002/jcp.10411
ER  -

TY  - JOUR
AU  - Akita, R. W.
AU  - Sliwkowski, M. X.
TI  - Preclinical studies with Erlotinib (Tarceva)
JA  - Semin. Oncol.
PY  - 2003///
VL  - 30
SP  - 15
EP  - 24
ER  -

TY  - JOUR
AU  - She, Q.
AU  - Solit, D.
AU  - Basso, A.
AU  - Moasser, M. M.
TI  - Resistance to gefitinib (ZD1839, Iressa) in PTEN null HER overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive PI3K/Akt pathway signaling
JA  - Clin. Cancer Res.
PY  - 2003///
VL  - 9
SP  - 4340
EP  - 4346
ER  -

TY  - JOUR
AU  - Bianco, R.
TI  - Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors
JA  - Oncogene
PY  - 2003///
VL  - 22
SP  - 2812
EP  - 2822
M3  - 10.1038/sj.onc.1206388
N1  - 10.1038/sj.onc.1206388
UR  - http://dx.doi.org/10.1038/sj.onc.1206388
ER  -

TY  - JOUR
AU  - Haas-Kogan, D. A.
TI  - Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib
JA  - J. Natl Cancer Inst.
PY  - 2005///
VL  - 97
SP  - 880
EP  - 887
ER  -

TY  - JOUR
AU  - McKillop, D.
TI  - Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor
JA  - Mol. Cancer Ther.
PY  - 2005///
VL  - 4
SP  - 641
EP  - 649
M3  - 10.1158/1535-7163.MCT-04-0329
N1  - 10.1158/1535-7163.MCT-04-0329
UR  - http://dx.doi.org/10.1158/1535-7163.MCT-04-0329
ER  -

TY  - JOUR
AU  - Fry, D. W.
TI  - Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor
JA  - Proc. Natl Acad. Sci. USA
PY  - 1998///
VL  - 95
SP  - 12022
EP  - 12027
M3  - 10.1073/pnas.95.20.12022
N1  - 10.1073/pnas.95.20.12022
UR  - http://dx.doi.org/10.1073/pnas.95.20.12022
ER  -

TY  - JOUR
AU  - Offterdinger, M.
AU  - Schofer, C.
AU  - Weipoltshammer, K.
AU  - Grunt, T. W.
TI  - c-erbB-3: a nuclear protein in mammary epithelial cells
JA  - J. Cell Biol.
PY  - 2002///
VL  - 157
SP  - 929
EP  - 939
M3  - 10.1083/jcb.200109033
N1  - 10.1083/jcb.200109033
UR  - http://dx.doi.org/10.1083/jcb.200109033
ER  -

TY  - JOUR
AU  - Meng, T. C.
AU  - Fukada, T.
AU  - Tonks, N. K.
TI  - Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo
JA  - Mol. Cell
PY  - 2002///
VL  - 9
SP  - 387
EP  - 399
M3  - 10.1016/S1097-2765(02)00445-8
N1  - 10.1016/S1097-2765(02)00445-8
UR  - http://dx.doi.org/10.1016/S1097-2765(02)00445-8
ER  -

TY  - JOUR
AU  - Tonks, N. K.
TI  - Redox Redux: Revisiting PTPs and the control of cell signaling
JA  - Cell
PY  - 2005///
VL  - 121
SP  - 667
EP  - 670
M3  - 10.1016/j.cell.2005.05.016
N1  - 10.1016/j.cell.2005.05.016
UR  - http://dx.doi.org/10.1016/j.cell.2005.05.016
ER  -

TY  - JOUR
AU  - Manning, G.
AU  - Whyte, D. B.
AU  - Martinez, R.
AU  - Hunter, T.
AU  - Sudarsanam, S.
TI  - The protein kinase complement of the human genome
JA  - Science
PY  - 2002///
VL  - 298
SP  - 1912
EP  - 1934
M3  - 10.1126/science.1075762
N1  - 10.1126/science.1075762
UR  - http://dx.doi.org/10.1126/science.1075762
ER  -

TY  - JOUR
AU  - Tsou, H. R.
TI  - 6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity
JA  - J. Med. Chem.
PY  - 2001///
VL  - 44
SP  - 2719
EP  - 2734
M3  - 10.1021/jm0005555
N1  - 10.1021/jm0005555
UR  - http://dx.doi.org/10.1021/jm0005555
ER  -

TY  - JOUR
AU  - Huron, D. R.
TI  - A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants
JA  - Clin. Cancer Res.
PY  - 2003///
VL  - 9
SP  - 1267
EP  - 1273
ER  -